Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

May

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL

FDA Approves Combination Regimen for Newly Diagnosed AML

Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors